文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

ReInvigorate研究——膈神经至膈肌刺激促进机械通气脱机:一项随机关键性临床试验方案

The ReInvigorate Study-phrenic nerve-to-diaphragm stimulation for weaning from mechanical ventilation: a protocol for a randomized pivotal clinical trial.
PubMed 文献 · Trials · 2024-08-02

ReInvigorate试验是一项前瞻性、多中心、随机对照关键性临床试验,评估Stimdia公司pdSTIM系统经皮颈膈神经刺激促进机械通气脱机的安全性和有效性。纳入机械通气至少96小时且至少一次脱机尝试失败的患者,主要疗效终点为成功脱离机械通气的时间(治疗组 vs 对照组),所有终点在30天或移除机械通气时评估,以先发生者为准。该研究在美国食品药品监督管理局的研究性器械豁免下进行,试验注册号NCT05998018,注册于2023年8月。

要点

  • pdSTIM系统经皮放置多极电极刺激颈膈神经,双侧激活膈肌收缩。
  • 纳入机械通气至少96小时且至少一次脱机尝试失败的患者。
  • 主要疗效终点为成功脱离机械通气的时间(治疗组 vs 对照组)。

核心结论

  • 所研究的技术可能为重症监护病房中难以脱机的机械通气患者提供一种首创疗法。

研究设计与样本

  • 前瞻性、多中心、随机对照关键性临床试验,评估Stimdia公司pdSTIM系统促进机械通气脱机的安全性和有效性。
  • pdSTIM系统采用经皮放置的多极电极刺激颈膈神经并双侧激活膈肌收缩。
  • 纳入机械通气至少96小时且至少一次脱机尝试失败的患者。
  • 主要疗效终点为成功脱离机械通气的时间(治疗组 vs 对照组)。
  • 次要终点包括快速浅呼吸指数及其他生理和系统特征,安全性将在主要分析和额外分析中总结。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the United States in 2017, there were an estimated 903,745 hospitalizations involving mechanical ventilation (MV). Complications from ventilation can result in longer hospital stays, increased risk of disability, and increased healthcare costs. It has been hypothesized that electrically pacing the diaphragm by phrenic nerve stimulation during mechanical ventilation may minimize or reverse diaphragm dysfunction, resulting in faster weaning. METHODS: The ReInvigorate Trial is a prospective, multicenter, randomized, controlled clinical trial evaluating the safety and efficacy of Stimdia's pdSTIM System for facilitating weaning from MV. The pdSTIM system employs percutaneously placed multipolar electrodes to stimulate the cervical phrenic nerves and activate contraction of the diaphragm bilaterally. Patients who were on mechanical ventilation for at least 96 h and who failed at least one weaning attempt were considered for enrollment in the study. The primary efficacy endpoint was the time to successful liberation from mechanical ventilation (treatment vs. control). Secondary endpoints will include the rapid shallow breathing index and other physiological and system characteristics. Safety will be summarized for both primary and additional analyses. All endpoints will be evaluated at 30 days or at the time of removal of mechanical ventilation, whichever is first. DISCUSSION: This pivotal study is being conducted under an investigational device exception with the U.S. Food and Drug Administration. The technology being studied could provide a first-of-kind therapy for difficult-to-wean patients on mechanical ventilation in an intensive care unit setting. TRIAL REGISTRATION: Clinicaltrials.gov, NCT05998018 , registered August 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Schaaf K, Mullin CM, Cunningham KW, et al. The ReInvigorate Study-phrenic nerve-to-diaphragm stimulation for weaning from mechanical ventilation: a protocol for a randomized pivotal clinical trial. Trials. 2024. PMID: 39095923. doi:10.1186/s13063-024-08355-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。